An observational study in Pain Management, C Section and Obstetric Pain, sponsored by Fundación Santa Fe de Bogota. Not yet recruiting at 1 site in Colombia. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Fundación Santa Fe de Bogota · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this observational study is to learn whether injecting a numbing medicine (levobupivacaine, a local anesthetic) into the surgical wound at the end of a cesarean delivery improves pain control in women who also receive spinal morphine. Spinal morphine is the standard pain treatment for cesarean delivery.
The main questions it aims to answer are:
Do women who receive wound infiltration with levobupivacaine report less pain at 24 hours, 48 hours, and 7 days after surgery than women who do not? Do they have a better quality of recovery, measured with the ObsQoR-10 questionnaire? Do they walk for the first time sooner, and do they need less additional ("rescue") pain medicine in the first 24 hours?
Researchers will compare two groups of women having a scheduled cesarean delivery under spinal anesthesia at Fundación Santa Fe de Bogotá (Bogotá, Colombia). In the first group, the surgeon routinely infiltrates the wound with levobupivacaine when closing. In the second group, the surgeon does not. The study team does not decide which women receive the medicine; this depends only on each surgeon's usual practice. All participants receive the same standard hospital pain treatment: spinal morphine, acetaminophen, and anti-inflammatory medicines.
Participants will:
Receive their usual cesarean care, with no extra procedures because of the study.
Answer short online questionnaires sent by WhatsApp or email at 24 hours, 48 hours, and 7 days after surgery. They will rate their pain on a 0-10 scale at each time point and their recovery with the ObsQoR-10 questionnaire at 24 hours.
Receive a phone call on day 7 reminding them to complete the last questionnaire.
Allow the research team to collect information from their medical record, such as the time to first walk and the use of rescue pain medicine.
The study plans to include 336 women over about 10 months.
Background and rationale Intrathecal morphine is the gold standard for analgesia after cesarean delivery. However, 25-80% of women still report moderate to severe pain during the first 24-48 hours. Poorly controlled pain may delay mobilization, increase systemic opioid use, interfere with breastfeeding and newborn care, and has been associated with chronic pain and postpartum depression. International recommendations (PROSPECT, ERAS) support multimodal analgesia. Local anesthetic wound infiltration is simple, inexpensive and reproducible, but evidence on its added benefit over intrathecal morphine is limited and heterogeneous in dose, technique and anatomical plane. Levobupivacaine, the pure S-enantiomer of bupivacaine, has lower cardiovascular and central nervous system toxicity.
Design This is a prospective, single-center, analytical observational cohort study at Fundación Santa Fe de Bogotá, a high-complexity teaching hospital in Bogotá, Colombia, with about 2,000 births per year. Patients are enrolled consecutively over 10 months. Exposure is determined only by the usual clinical practice of each attending obstetrician. The investigators do not assign, randomize or suggest the exposure.
Exposure Exposed cohort: subcutaneous and subfascial infiltration with levobupivacaine 0.75%, 75 mg (one 10 mL ampoule diluted in 10 mL of saline), after closure of the aponeurosis. The drug is Bupinest®, INVIMA registration 2016 M-013339-R2. The total local anesthetic dose, including the spinal dose, stays within the maximum of 2 mg/kg.
Unexposed cohort: no wound infiltration.
Standard institutional analgesia (both cohorts) Spinal anesthesia with intrathecal morphine 100 mcg and fentanyl 25 mcg. Ketorolac 30 mg IV after delivery of the newborn. Acetaminophen 1 g IV at the end of surgery. During the 48-hour hospital stay: oral celecoxib every 12 hours (unless contraindicated), oral acetaminophen 1 g every 8 hours, and IV hyoscine butylbromide 20 mg every 8 hours.
Rescue systemic opioid for pain score >7 or at the patient's request.
Blinding and data collection Outcome assessment and statistical analysis are blinded to exposure. Patient-reported outcomes (pain scale and the validated Spanish version of the ObsQoR-10) are self-administered through automated REDCap surveys sent by WhatsApp or email, which reduces inter-observer variability. Clinical and surgical data are taken from the electronic medical record.
Sample size Sample size was calculated with Epidat 4.2 for comparison of two independent means, using 24-hour pain scores from published data. The parameters were 95% confidence, 80% power and a 1:1 ratio. The result is 336 participants (168 per cohort).
Statistical analysis Pain trajectory (24 h, 48 h, 7 days): linear mixed model for repeated measures. Fixed effects are exposure, time and the exposure × time interaction; the patient is a random effect. Mean between-group differences at each time point are reported with 95% CIs. If model assumptions are not met, robust or ordinal models will be used.
Secondary outcomes:
Time to first ambulation: t-test or Mann-Whitney, and Kaplan-Meier with log-rank if exact times are available.
Rescue analgesia: chi-square or Fisher's exact test, and logistic regression. ObsQoR-10: as a continuous score, and dichotomized at ≥70 points as good recovery.
Adjusted models: multivariable models adjust for confounders, including maternal age, BMI and previous cesarean delivery.
Exploratory subgroups: age, parity, BMI category and previous cesarean delivery.
Significance is set at p \<0.05. The analysis will be done in Rstudio.
Ethics The study is classified as minimal risk under Colombian Resolution 8430 of 1993. It has been approved by the Corporate Research Ethics Committee (CCEI) of Fundación Santa Fe de Bogotá. As an observational Phase IV study of a marketed medicine, it will be notified to INVIMA, the Colombian National Food and Drug Surveillance Institute, before enrollment begins. All participants give electronic informed consent through REDCap. Results will be published regardless of direction.
426 studies on the registry are indexed under Labor Pain; 76 are open to participants now.
This study's planned enrollment of 336 is above the median of 140 across 63 observational studies indexed under Labor Pain.
Browse Labor Pain studies →Fundación Santa Fe de Bogota is the lead sponsor of 27 studies on the registry; 11 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Women admitted for cesarean delivery to the Obstetrics Service of Fundación Santa Fe de Bogotá, a private, high-complexity university hospital in Bogotá, Colombia, which attends approximately 2,000 births per year.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Women undergoing scheduled cesarean delivery under spinal anesthesia with intrathecal morphine and fentanyl whose attending obstetrician, as part of usual clinical practice, performs subcutaneous and subfascial wound infiltration with levobupivacaine 0.75% (75 mg, one 10 mL ampoule diluted in 10 mL of saline) after closure of the aponeurosis. Participants also receive standard institutional multimodal analgesia: ketorolac, acetaminophen, celecoxib and hyoscine butylbromide, with systemic opioid rescue as needed. Exposure is not assigned by the investigators.
Drug: Levobupivacaine · Drug: Intrathecal Morphine
Women undergoing scheduled cesarean delivery under spinal anesthesia with intrathecal morphine and fentanyl whose attending obstetrician, as part of usual clinical practice, does not perform wound infiltration with local anesthetic. Participants receive the same standard institutional multimodal analgesia: ketorolac, acetaminophen, celecoxib and hyoscine butylbromide, with systemic opioid rescue as needed. Exposure is not assigned by the investigators.
Drug: Intrathecal Morphine
Subcutaneous and subfascial wound infiltration with levobupivacaine 0.75%, 75 mg (one 10 mL ampoule diluted in 10 mL of saline, total 20 mL), performed after closure of the aponeurosis at the end of cesarean delivery, as part of the attending obstetrician's usual practice. Given in addition to the same standard institutional multimodal analgesia received by all participants: intrathecal morphine plus fentanyl, ketorolac, acetaminophen, celecoxib and hyoscine butylbromide, with systemic opioid rescue as needed. Not assigned by the investigators.
Also known as: Bupinest®, Levobupivacaine hydrochloride
Single-dose intrathecal morphine plus fentanyl given with spinal anesthesia for cesarean delivery, as part of the standard institutional multimodal analgesia protocol (with ketorolac, acetaminophen, celecoxib and hyoscine butylbromide; systemic opioid rescue as needed).
Also known as: Spinal morphine
Postoperative pain intensity (Visual Analog Scale)
Patient-reported pain intensity on a 0 to 10 Visual Analog Scale (0 = no pain, 10 = worst imaginable pain); higher scores indicate worse pain. Self-administered through automated REDCap surveys sent by WhatsApp or email, with outcome assessors and the statistician blinded to exposure. Pain trajectories will be compared between cohorts using a linear mixed model for repeated measures (fixed effects: cohort, time and cohort-by-time interaction; patient as random effect), reporting mean between-group differences with 95% confidence intervals at each time point.
Time frame: 24 hours, 48 hours and 7 days after cesarean delivery
Quality of obstetric recovery (ObsQoR-10 score)
Patient-reported quality of recovery measured with the validated Spanish version of the Obstetric Quality of Recovery-10 questionnaire (ObsQoR-10-Spanish). It includes 10 items scored 0 to 10, for a total score of 0 to 100; higher scores indicate better recovery. Self-administered through an automated REDCap survey. Compared between cohorts as a continuous variable.
Time frame: 24 hours after cesarean delivery
Proportion of participants with good obstetric recovery (ObsQoR-10 score ≥70)
Percentage of participants classified as having good recovery (ObsQoR-10 total score ≥70 points) versus poor recovery (\<70 points), using the cut-off reported in the literature. Compared between cohorts with risk ratios or odds ratios and 95% confidence intervals.
Time frame: 24 hours after cesarean delivery
Time to first ambulation
Time in hours from the end of cesarean delivery until the participant walks for the first time, obtained from the medical record. Compared between cohorts as a continuous variable, and with time-to-event analysis (Kaplan-Meier, log-rank test) if exact times are available.
Time frame: From end of surgery up to 24 hours after cesarean delivery
Use of rescue analgesia
Percentage of participants who require rescue systemic opioid analgesia in addition to the standard institutional regimen (given for a pain score \>7 or at the patient's request), obtained from the medical record. Compared between cohorts with risk ratios or odds ratios and 95% confidence intervals, adjusted with multivariable logistic regression.
Time frame: First 24 hours after cesarean delivery
Plan to share: No — Individual participant data will not be shared outside the research team, as the informed consent approved by the institutional ethics committee does not include authorization for data sharing with external researchers. Data will be stored confidentially in the institutional REDCap platform of Fundación Santa Fe de Bogotá for at least 5 years. Aggregated results will be published regardless of direction.
Start is estimated for Oct 2026; primary completion for Jul 2027, 9 months later.
Of 31 non-industry observational studies under Labor Pain, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 32. This study's planned 9 months is close to that.
Counting every sponsor, half of 32 studies reached it within 9 months; a quarter within 6 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundación Santa Fe de Bogota